SynAct Pharma Valuation

Q: What is the Fair Price of SYNACT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

SYNACT (SEK11.2) is trading below our estimate of [[fair value]] (SEK92.77)

Is SYNACT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SYNACT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow

Simply Wall St

SEK 92.77

Fair Value

87.9% undervalued

Number of Analysts

Below Fair Value: SYNACT (SEK11.2) is trading below our estimate of fair value (SEK92.77)

Significantly Below Fair Value: SYNACT is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SYNACT?

Key metric: As SYNACT is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for SYNACT. This is calculated by dividing SYNACT's market cap by their current book value.
What is SYNACT's PB Ratio?
PB Ratio	2.7x
Book	SEK 169.16m
Market Cap	SEK 462.52m

SYNACT key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	-6.6x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does SYNACT's PB Ratio compare to its peers?

The above table shows the PB ratio for SYNACT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	6x
ISOFOL Isofol Medical	4.4x	n/a	SEK 400.6m
IMMU Mendus	0.6x	-15.3%	SEK 415.9m
INIT Initiator Pharma	16.6x	31.7%	SEK 402.1m
MVIR Medivir	2.4x	47.5%	SEK 335.4m
SYNACT SynAct Pharma	2.7x	99.2%	SEK 462.5m

Price-To-Book vs Peers: SYNACT is good value based on its Price-To-Book Ratio (2.7x) compared to the peer average (6x).

Price to Book Ratio vs Industry

How does SYNACT's PB Ratio compare vs other companies in the SE Biotechs Industry?

10 Companies	Price / Book	Estimated Growth	Market Cap
IVACC Intervacc	0.4x	26.6%	US$6.11m
COMBI CombiGene	0.5x	n/a	US$3.94m
QUIA Quia Pharma	0.5x	n/a	US$1.42m
SCOL Scandion Oncology	0.4x	69.7%	US$1.41m

10 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: SYNACT is expensive based on its Price-To-Book Ratio (2.7x) compared to the Swedish Biotechs industry average (2.6x).

Price to Book Ratio vs Fair Ratio

What is SYNACT's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SYNACT PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	2.7x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate SYNACT's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Price Target

Consensus Narrative from 1 Analyst

SEK 16.00

Fair Value

30.0% undervalued

Number of Analysts

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/08 15:01
End of Day Share Price	2025/01/08 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

SynAct Pharma AB is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Patrik Ling	DNB Markets
Carl Ramanius	Redeye